Company intelligence / Profile preview

Translumina Therapeutics

Hechingen, Baden-Württemberg, Germanytranslumina.com ↗

Ownership: Private
Employees: ~284
Development stage: Commercial

Overview

Translumina’s drug-eluting stents, especially Yukon Choice PC, have demonstrated long-term safety and efficacy in major international studies. Their technologies are CE-certified and widely adopted in over 60 countries. The company has a strong record of innovation in polymer coatings to reduce late adverse events post-stenting.

Therapeutic areas: Cardiovascular
Modalities: DeviceDrug-eluting stentDrug-coated balloon
Industry: Therapeutic Medical Devices

Drug pipeline

3 assets

YUKON

Commercial

Indications: Coronary artery disease

2 more assets in the full pipeline.

Request access →

Partnerships

German Heart Centre Munich for R&D/clinical validationstrategic partnership with engineering institutes/hospitals worldwide

Beyond the preview

Go deeper on Translumina Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Translumina Therapeutics.

Explore the full profile